102 related articles for article (PubMed ID: 27363833)
1. Upregulation of Key Molecules for Targeted Imaging and Therapy.
Taelman VF; Radojewski P; Marincek N; Ben-Shlomo A; Grotzky A; Olariu CI; Perren A; Stettler C; Krause T; Meier LP; Cescato R; Walter MA
J Nucl Med; 2016 Nov; 57(11):1805-1810. PubMed ID: 27363833
[TBL] [Abstract][Full Text] [Related]
2. Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro.
Jin XF; Auernhammer CJ; Ilhan H; Lindner S; Nölting S; Maurer J; Spöttl G; Orth M
J Nucl Med; 2019 Sep; 60(9):1240-1246. PubMed ID: 30796167
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions.
Heidari P; Kunawudhi A; Martinez-Quintanilla J; Szretter A; Shah K; Mahmood U
Theranostics; 2018; 8(12):3380-3391. PubMed ID: 29930736
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment.
Guenter R; Aweda T; Carmona Matos DM; Jang S; Whitt J; Cheng YQ; Liu XM; Chen H; Lapi SE; Jaskula-Sztul R
Surgery; 2020 Jan; 167(1):189-196. PubMed ID: 31629542
[TBL] [Abstract][Full Text] [Related]
5. Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model.
Chereau E; Durand L; Frati A; Prignon A; Talbot JN; Rouzier R
Anticancer Res; 2013 Aug; 33(8):3015-9. PubMed ID: 23898054
[TBL] [Abstract][Full Text] [Related]
6. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
7. Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT.
Van Binnebeek S; Koole M; Terwinghe C; Baete K; Vanbilloen B; Haustermans K; Clement PM; Bogaerts K; Verbruggen A; Nackaerts K; Van Cutsem E; Verslype C; Mottaghy FM; Deroose CM
Nuklearmedizin; 2016 Jun; 55(3):104-14. PubMed ID: 27056060
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.
Evans JS; Beaumont J; Braga M; Masrour N; Mauri F; Beckley A; Butt S; Karali CS; Cawthorne C; Archibald S; Aboagye EO; Sharma R
Eur J Cancer; 2022 Nov; 176():110-120. PubMed ID: 36208569
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
[TBL] [Abstract][Full Text] [Related]
10. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Liu Z; Marquez M; Nilsson S; Holmberg AR
Oncol Rep; 2008 Jul; 20(1):151-4. PubMed ID: 18575731
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Haug AR; Auernhammer CJ; Wängler B; Schmidt GP; Uebleis C; Göke B; Cumming P; Bartenstein P; Tiling R; Hacker M
J Nucl Med; 2010 Sep; 51(9):1349-56. PubMed ID: 20720050
[TBL] [Abstract][Full Text] [Related]
13. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy.
Kratochwil C; Mavriopoulou E; Rath D; Afshar-Oromieh A; Apostolopoulos D; Haufe S; Mier W; Haberkorn U; Giesel FL
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):116-20. PubMed ID: 24382404
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors.
Guenter RE; Aweda T; Carmona Matos DM; Whitt J; Chang AW; Cheng EY; Liu XM; Chen H; Lapi SE; Jaskula-Sztul R
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31163616
[TBL] [Abstract][Full Text] [Related]
16. A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors.
Zheng N; Dai W; Du W; Zhang H; Lei L; Zhang H; Wang X; Wang J; Zhang X; Gao J; Zhang Q
Mol Pharm; 2012 May; 9(5):1175-88. PubMed ID: 22435704
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression.
Rostomily RC; Elias M; Deng M; Elias P; Born DE; Muballe D; Silbergeld DL; Futran N; Weymuller EA; Mankoff DA; Eary J
Head Neck; 2006 Apr; 28(4):305-12. PubMed ID: 16470879
[TBL] [Abstract][Full Text] [Related]
18. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
[TBL] [Abstract][Full Text] [Related]
19. An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression.
Stelter L; Amthauer H; Rexin A; Pinkernelle J; Schulz P; Michel R; Denecke T; Stiepani H; Hamm B; Wiedenmann B; Scholz A
Neuroendocrinology; 2008; 87(4):233-42. PubMed ID: 18025811
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
